Browse
Submit Data
Databases
API
Help

Dataset Information

10 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Case of COVID-19 and Pneumocystis jirovecii Coinfection.

ABSTRACT:

SUBMITTER: Menon AA

PROVIDER: S-EPMC7328312 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Pneumocystis jirovecii

Project description:Pathogenic fungus that causes pneumonia in immunocompromised persons

| PRJNA20531 | ENA

Pneumocystis jirovecii

Project description:Pneumocystis jirovecii Metagenome

| PRJNA782857 | ENA

Pneumocystis jirovecii

Project description:Metagenomic next-generation sequencing and conventional tests unravel pathogen profiles in infected patients undergoing allogeneic hematopoietic stem cell transplantation in Jilin Province

| PRJNA1058277 | ENA

Pneumocystis jirovecii

Project description:Alterations of lung microbiota in lung transplant recipients with Pneumocystis jirovecii pneumonia.

| PRJNA1033798 | ENA

Pneumocystis jirovecii

Project description:Pneumocystis jirovecii msg genes repertoires

| PRJNA936793 | ENA

No Change of Pneumocystis jirovecii Pneumonia after the COVID-19 Pandemic: Multicenter Time-Series Analyses.

Project description:Consolidated infection control measures imposed by the government and hospitals during COVID-19 pandemic resulted in a sharp decline of respiratory viruses. Based on the issue of whether Pneumocystis jirovecii could be transmitted by airborne and acquired from the environment, we assessed changes in P. jirovecii pneumonia (PCP) cases in a hospital setting before and after COVID-19. We retrospectively collected data of PCP-confirmed inpatients aged ≥18 years (N = 2922) in four university-affiliated hospitals between January 2015 and June 2021. The index and intervention dates were defined as the first time of P. jirovecii diagnosis and January 2020, respectively. We predicted PCP cases for post-COVID-19 and obtained the difference (residuals) between forecasted and observed cases using the autoregressive integrated moving average (ARIMA) and the Bayesian structural time-series (BSTS) models. Overall, the average of observed PCP cases per month in each year were 36.1 and 47.3 for pre- and post-COVID-19, respectively. The estimate for residuals in the ARIMA model was not significantly different in the total PCP-confirmed inpatients (7.4%, p = 0.765). The forecasted PCP cases by the BSTS model were not significantly different from the observed cases in the post-COVID-19 (-0.6%, 95% credible interval; -9.6~9.1%, p = 0.450). The unprecedented strict non-pharmacological interventions did not affect PCP cases.

| S-EPMC8624436 | biostudies-literature

Pneumocystis jirovecii pneumonia in COVID-19: an overlooked clinical entity-Response to "Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19".

Project description: Not available

| S-EPMC8647515 | biostudies-literature

Pneumocystis jirovecii RU12

Project description:Pneumocystis

| PRJNA223508 | ENA

Pneumocystis jirovecii TSA

Project description:Transcriptome of Pneumocystis jirovecii during human Pneumocystis pneumonia

| PRJEB370 | ENA

Pneumocystis jirovecii RU7

Project description:Pneumocystis